IP Library Granted Patent US 11,717,510
Granted Patent B2
US 11,717,510 · App. 17/229,061 · Granted Aug 8, 2023

Methods and compositions for daily ophthalmic administration of phentolamine to improve visual performance

Inventor: Alan Meyer (North Riverside, IL)
Assignee: Ocuphire Pharma, Inc.
A61K31/417A61K47/12A61K47/26A61P27/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,717,510
App. No.
17/229,061
Granted
Aug 8, 2023
Kind
B2
Abstract

The invention provides methods, compositions, and kits containing phentolamine for improving visual performance. In particular, the invention provides improvement in visual performance, such as improvement in visual acuity, by daily ophthalmic administration of a phentolamine solution to an eye of a patient at or near the bedtime of the patient for an extended duration while minimizing the occurrence of adverse side effects, such as eye redness during the patient's waking hours.

Claims (26)

1. A method for improving visual performance during low-light conditions, comprising daily ophthalmic administration of an aqueous ophthalmic solution comprising about 1% (w/v) phentolamine mesylate to an eye of a patient at or near the bedtime of the patient, to thereby improve visual performance under low-light conditions, wherein the method is characterized by:

the patient experiences an increase in eye redness of no more than one grade measured using the CCLRU Redness Grading Scale during the patient's waking hours compared to the patient's level of eye redness without receiving said aqueous ophthalmic solution;

the aqueous ophthalmic solution is administered to the eye of the patient in an amount sufficient to provide improved visual performance for at least twenty-four hours;

the aqueous ophthalmic solution is administered as an eye drop to the eye of the patient;

within 8 hours after administration of phentolamine mesylate to the patient's eye, the amount of eye redness returns to the baseline amount of eye redness present in the patient's eye prior to said administration of phentolamine mesylate; and

the patient is a human.

2. The method of claim 1 , wherein the low-light conditions are nighttime conditions.

3. The method of claim 1 , wherein the improvement in visual performance is an improvement in visual acuity.

4. The method of claim 2 , wherein the improvement in visual performance is an improvement in visual acuity.

5. The method of claim 1 , wherein the improvement in visual performance is an improvement in contrast sensitivity.

6. The method of claim 2 , wherein the improvement in visual performance is an improvement in contrast sensitivity.

7. The method of claim 1 , wherein the aqueous ophthalmic solution is administered within 1 hour of the patient's bedtime.

8. The method of claim 2 , wherein the aqueous ophthalmic solution is administered within 1 hour of the patient's bedtime.

9. The method of claim 4 , wherein the aqueous ophthalmic solution is administered within 1 hour of the patient's bedtime.

10. The method of claim 1 , wherein the aqueous ophthalmic solution comprises 1% (w/v) phentolamine mesylate.

11. The method of claim 2 , wherein the aqueous ophthalmic solution comprises 1% (w/v) phentolamine mesylate.

12. The method of claim 4 , wherein the aqueous ophthalmic solution comprises 1% (w/v) phentolamine mesylate.

13. The method of claim 1 , wherein the aqueous ophthalmic solution comprises water, a polyol, and about 1% (w/v) phentolamine mesylate.

14. The method of claim 2 , wherein the aqueous ophthalmic solution comprises water, a polyol, and about 1% (w/v) phentolamine mesylate.

15. The method of claim 4 , wherein the aqueous ophthalmic solution comprises water, a polyol, and about 1% (w/v) phentolamine mesylate.

16. The method of claim 1 , wherein the aqueous ophthalmic solution comprises water, mannitol, sodium acetate, and about 1% (w/v) phentolamine mesylate.

17. The method of claim 2 , wherein the aqueous ophthalmic solution comprises water, mannitol, sodium acetate, and about 1% (w/v) phentolamine mesylate.

18. The method of claim 4 , wherein the aqueous ophthalmic solution comprises water, mannitol, sodium acetate, and about 1% (w/v) phentolamine mesylate.

19. The method of claim 1 , wherein the aqueous ophthalmic solution is administered as one eye drop to the eye of the patient near the bedtime of the patient.

20. The method of claim 2 , wherein the aqueous ophthalmic solution is administered as one eye drop to the eye of the patient near the bedtime of the patient.

21. The method of claim 4 , wherein the aqueous ophthalmic solution is administered as one eye drop to the eye of the patient near the bedtime of the patient.

Assignments (4)
SECURITY INTEREST Recorded Apr 21, 2026
From: OPUS GENETICS, INC.
To: OPCM SA LLC, AS PURCHASER AGENT FOR THE SECURED PARTIES
Reel/Frame 075478/0138 →
CHANGE OF NAME Recorded Dec 27, 2024
From: OCUPHIRE PHARMA, INC.
To: OPUS GENETICS, INC.
Reel/Frame 069793/0460 →
MERGER Recorded Jun 14, 2023
From: OCULARIS PHARMA, LLC
To: OCUPHIRE PHARMA, INC.
Reel/Frame 063944/0922 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 14, 2023
From: MEYER, ALAN R.
To: OCULARIS PHARMA, LLC
Reel/Frame 063944/0943 →
Continuity (5)
Continuation 15714475 · Sep 25, 2017
Continuation 14754965 · Jun 30, 2015
Continuation 14169342 · Jan 31, 2014
Provisional Application 61759542 · Feb 1, 2013
Related Publication 20210338638A1 · Nov 4, 2021
Cited By (5)
US 12,201,615 US 12,201,616 US 12,350,366 US 12,576,066 US 12,576,067